A citation-based method for searching scientific literature

Harry D Bear, Stewart Anderson, Ann Brown, Roy Smith, Eleftherios P Mamounas, Bernard Fisher, Richard Margolese, Heather Theoret, Atilla Soran, D Lawrence Wickerham, Norman Wolmark. J Clin Oncol 2003
Times Cited: 768







List of co-cited articles
500 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
38

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
32

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, R G Margolese, A B Cruz, E R Fisher, D L Wickerham, N Wolmark,[...]. J Clin Oncol 1997
30

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, Harry D Bear, Charles E Geyer, Morton S Kahlenberg, André Robidoux, Richard G Margolese, James L Hoehn, Victor G Vogel, Shaker R Dakhil,[...]. J Clin Oncol 2008
28


Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim,[...]. N Engl J Med 2017
495
22

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Roy E Smith, Charles E Geyer, Eleftherios P Mamounas, Bernard Fisher, Ann M Brown, Andre Robidoux, Richard Margolese, Morton S Kahlenberg,[...]. J Clin Oncol 2006
649
21

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im,[...]. Lancet Oncol 2012
17

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Judy C Boughey, Vera J Suman, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, A Marilyn Leitch, Henry M Kuerer, Monet Bowling, Teresa S Flippo-Morton,[...]. JAMA 2013
655
17

Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Eleftherios P Mamounas, Stewart J Anderson, James J Dignam, Harry D Bear, Thomas B Julian, Charles E Geyer, Alphonse Taghian, D Lawrence Wickerham, Norman Wolmark. J Clin Oncol 2012
301
17

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
625
17

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
Thorsten Kuehn, Ingo Bauerfeind, Tanja Fehm, Barbara Fleige, Maik Hausschild, Gisela Helms, Annette Lebeau, Cornelia Liedtke, Gunter von Minckwitz, Valentina Nekljudova,[...]. Lancet Oncol 2013
601
16

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, E R Fisher, D L Wickerham, M Begovic, A DeCillis, A Robidoux,[...]. J Clin Oncol 1998
16

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
Abigail S Caudle, Wei T Yang, Savitri Krishnamurthy, Elizabeth A Mittendorf, Dalliah M Black, Michael Z Gilcrease, Isabelle Bedrosian, Brian P Hobbs, Sarah M DeSnyder, Rosa F Hwang,[...]. J Clin Oncol 2016
329
13

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2007
791
13


Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis. J Natl Cancer Inst 2005
734
13

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.
Jean-Francois Boileau, Brigitte Poirier, Mark Basik, Claire M B Holloway, Louis Gaboury, Lucas Sideris, Sarkis Meterissian, Angel Arnaout, Muriel Brackstone, David R McCready,[...]. J Clin Oncol 2015
329
12

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
11

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
482
11

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
496
10

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
W Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Mei Liu, Andrew Walls, Alex Bousamra, Maheshwari Ramineni, Bruno Sinn,[...]. J Clin Oncol 2017
241
10

Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Judy C Boughey, Linda M McCall, Karla V Ballman, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, A Marilyn Leitch, Teresa Flippo-Morton, Kelly K Hunt. Ann Surg 2014
204
10

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
Laura M Spring, Arjun Gupta, Kerry L Reynolds, Michele A Gadd, Leif W Ellisen, Steven J Isakoff, Beverly Moy, Aditya Bardia. JAMA Oncol 2016
141
10

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J A van der Hage, C J van de Velde, J P Julien, M Tubiana-Hulin, C Vandervelden, L Duchateau. J Clin Oncol 2001
726
10

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
258
10

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Nehmat Houssami, Petra Macaskill, Gunter von Minckwitz, Michael L Marinovich, Eleftherios Mamounas. Eur J Cancer 2012
268
9


Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Rita Nanda, Minetta C Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne Wallace, A Jo Chien, Andres Forero-Torres, Erin Ellis, Heather Han,[...]. JAMA Oncol 2020
145
9

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
394
9

Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
Judy C Boughey, Karla V Ballman, Huong T Le-Petross, Linda M McCall, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, Eric C Feliberti, Kelly K Hunt. Ann Surg 2016
202
8

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Manfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, David Cameron, Lisa A Carey, Massimo Cristofanilli, Carsten Denkert, Wolfgang Eiermann, Michael Gnant, Jay R Harris,[...]. Ann Surg Oncol 2012
292
8

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
Gunter von Minckwitz, Günter Raab, Angelika Caputo, Martin Schütte, Jörn Hilfrich, Jens U Blohmer, Bernd Gerber, Serban D Costa, Elisabeth Merkle, Holger Eidtmann,[...]. J Clin Oncol 2005
287
8


How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Anita Mamtani, Andrea V Barrio, Tari A King, Kimberly J Van Zee, George Plitas, Melissa Pilewskie, Mahmoud El-Tamer, Mary L Gemignani, Alexandra S Heerdt, Lisa M Sclafani,[...]. Ann Surg Oncol 2016
141
8

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Marjorie C Green, Aman U Buzdar, Terry Smith, Nuhad K Ibrahim, Vicente Valero, Marguerite F Rosales, Massimo Cristofanilli, Daniel J Booser, Lajos Pusztai, Edgardo Rivera,[...]. J Clin Oncol 2005
302
8

Preoperative chemotherapy for women with operable breast cancer.
J S D Mieog, J A van der Hage, C J H van de Velde. Cochrane Database Syst Rev 2007
228
8


Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
Mila Donker, Marieke E Straver, Jelle Wesseling, Claudette E Loo, Margaret Schot, Caroline A Drukker, Harm van Tinteren, Gabe S Sonke, Emiel J Th Rutgers, Marie-Jeanne T F D Vrancken Peeters. Ann Surg 2015
185
7

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007
7

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser,[...]. Lancet 2010
765
7

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
David N Krag, Stewart J Anderson, Thomas B Julian, Ann M Brown, Seth P Harlow, Joseph P Costantino, Takamaru Ashikaga, Donald L Weaver, Eleftherios P Mamounas, Lynne M Jalovec,[...]. Lancet Oncol 2010
917
7

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Starosławska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini,[...]. Lancet Oncol 2016
317
7

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
607
7

Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.
Kelly K Hunt, Min Yi, Elizabeth A Mittendorf, Cynthia Guerrero, Gildy V Babiera, Isabelle Bedrosian, Rosa F Hwang, Henry M Kuerer, Merrick I Ross, Funda Meric-Bernstam. Ann Surg 2009
172
7

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Armando E Giuliano, Kelly K Hunt, Karla V Ballman, Peter D Beitsch, Pat W Whitworth, Peter W Blumencranz, A Marilyn Leitch, Sukamal Saha, Linda M McCall, Monica Morrow. JAMA 2011
7

Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
Sean E McGuire, Ana M Gonzalez-Angulo, Eugene H Huang, Susan L Tucker, Shu-Wan C Kau, Tse-Kuan Yu, Eric A Strom, Julia L Oh, Wendy A Woodward, Welela Tereffe,[...]. Int J Radiat Oncol Biol Phys 2007
149
7

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Matthew P Goetz, John A Olson,[...]. N Engl J Med 2018
793
7

Defining the benefits of neoadjuvant chemotherapy for breast cancer.
Anne F Schott, Daniel F Hayes. J Clin Oncol 2012
97
6

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren,[...]. Lancet 2012
848
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.